- Home
- SNPX vs OKTA Comparison
SNPX vs OKTA Comparison
Compare SNPX & OKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- OKTA
- Stock Information
- Founded
- SNPX 2012
- OKTA 2009
- Country
- SNPX United States
- OKTA United States
- Employees
- SNPX 5
- OKTA N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- OKTA Computer Software: Prepackaged Software
- Sector
- SNPX Health Care
- OKTA Technology
- Exchange
- SNPX Nasdaq
- OKTA Nasdaq
- Market Cap
- SNPX 3.3M
- OKTA N/A
- IPO Year
- SNPX N/A
- OKTA 2017
- Fundamental
- Price
- SNPX $2.43
- OKTA $104.63
- Analyst Decision
- SNPX Strong Buy
- OKTA Buy
- Analyst Count
- SNPX 1
- OKTA 35
- Target Price
- SNPX $14.00
- OKTA $114.97
- AVG Volume (30 Days)
- SNPX 7.8K
- OKTA 3.7M
- Earning Date
- SNPX 05-14-2025
- OKTA 05-28-2025
- Dividend Yield
- SNPX N/A
- OKTA N/A
- EPS Growth
- SNPX N/A
- OKTA N/A
- EPS
- SNPX N/A
- OKTA 0.15
- Revenue
- SNPX N/A
- OKTA $2,610,000,000.00
- Revenue This Year
- SNPX N/A
- OKTA $11.88
- Revenue Next Year
- SNPX N/A
- OKTA $10.00
- P/E Ratio
- SNPX N/A
- OKTA $693.63
- Revenue Growth
- SNPX N/A
- OKTA 15.33
- 52 Week Low
- SNPX $2.15
- OKTA $70.56
- 52 Week High
- SNPX $6.22
- OKTA $118.07
- Technical
- Relative Strength Index (RSI)
- SNPX 35.26
- OKTA 46.27
- Support Level
- SNPX $2.15
- OKTA $102.91
- Resistance Level
- SNPX $2.78
- OKTA $118.07
- Average True Range (ATR)
- SNPX 0.17
- OKTA 3.65
- MACD
- SNPX -0.02
- OKTA -1.59
- Stochastic Oscillator
- SNPX 31.02
- OKTA 9.20
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.